More biopharma layoffs are hitting New Jersey, this time from Merck & Co., in the latest phase of headcount reductions attributed to its $3 billion cost-cutting plan announced last July. The latest ...

Merck is planning further cuts at its headquarters in New Jersey as part of an ongoing restructuring effort. In a filing with the state Department of Labor & Workforce Development, the pharmaceutical ...

RAHWAY, N.J.- Merck is cutting dozens of jobs at its Rahway headquarters. According to a notice filed with New Jersey's Department of Labor, 88 employees are being laid off, effective September 4, ...

Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...

NEW YORK, April 22 (Reuters) - Inhibrx Biosciences (INBX.O), opens new tab has drawn interest from drugmakers including Merck & Co (MRK.N), opens new tab, Germany’s Merck KGaA (MRCG.DE), opens new tab ...

Just a few weeks after President Donald Trump’s December promise that prescription drug prices would plummet "fast and furious," Patricia Brown checked into a California clinic for an infusion of ...

Merck MRK0.84%increase; up pointing triangle has reached a nearly $6 billion cash deal to buy the cancer biotech Terns Pharmaceuticals and its promising leukemia treatment. If it proves to work safely ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Facing vaccine pressures in multiple markets, Merck & Co. is pruning the ranks at one of its key U.S. production facilities. In a Worker Adjustment and Retraining Notification (WARN) Act alert filed ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Merck & Co. trades at a deep discount, reflecting market fears over the 2028 Keytruda patent cliff despite robust Q3 2025 results and pipeline momentum. MRK's diversification strategy is gaining ...